Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;20(2):538-545.
doi: 10.1111/ajt.15592. Epub 2019 Oct 3.

Deletion of Donor-Reactive T Cell Clones After Human Liver Transplant

Free PMC article

Deletion of Donor-Reactive T Cell Clones After Human Liver Transplant

Thomas M Savage et al. Am J Transplant. .
Free PMC article


We recently developed a high throughput T cell receptor β chain (TCRβ) sequencing-based approach to identifying and tracking donor-reactive T cells. To address the role of clonal deletion in liver allograft tolerance, we applied this method in samples from a recent randomized study, ITN030ST, in which immunosuppression withdrawal was attempted within 2 years of liver transplantation. We identified donor-reactive T cell clones via TCRβ sequencing following a pre-transplant mixed lymphocyte reaction and tracked these clones in the circulation following transplantation in 3 tolerant and 5 non-tolerant subjects. All subjects showed a downward trend and significant reductions in donor-reactive TCRβ sequences were detected post-transplant in 6 of 8 subjects, including 2 tolerant and 4 non-tolerant recipients. Reductions in donor-reactive TCRβ sequences were greater than those of all other TCRβ sequences, including 3rd party-reactive sequences, in all 8 subjects, demonstrating an impact of the liver allograft after accounting for repertoire turnover. Although limited by patient number and heterogeneity, our results suggest that partial deletion of donor-reactive T cell clones may be a consequence of liver transplantation and does not correlate with success or failure of early immunosuppression withdrawal. These observations underscore the organ- and/or protocol-specific nature of tolerance mechanisms in humans.

Keywords: T cell biology; basic (laboratory) research/science; immunobiology; liver transplantation/hepatology; monitoring: immune; tolerance.

Conflict of interest statement


The authors of this manuscript have conflicts of interest to disclose as described by the American Journal of Transplantation. H.R. owns stock in Adaptive Biotechnologies, Inc. The other authors have no conflicts of interest to disclose

Similar articles

See all similar articles

Publication types

LinkOut - more resources